What is Wedbush's Estimate for Ardelyx Q2 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities researchers at Wedbush issued their Q2 2026 EPS estimates for Ardelyx in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will post earnings of $0.01 per share for the quarter. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's Q3 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.06 EPS.

ARDX has been the topic of a number of other research reports. Jefferies Financial Group reduced their price objective on Ardelyx from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, January 2nd. Raymond James restated a "strong-buy" rating and set a $13.00 target price (down previously from $15.00) on shares of Ardelyx in a research report on Friday, February 21st. Scotiabank initiated coverage on shares of Ardelyx in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price on the stock. LADENBURG THALM/SH SH reissued a "buy" rating and set a $11.00 price target on shares of Ardelyx in a research note on Friday, March 7th. Finally, Piper Sandler raised Ardelyx to a "hold" rating in a research note on Wednesday, March 12th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Ardelyx presently has an average rating of "Moderate Buy" and an average target price of $10.61.

Ardelyx Price Performance

Shares of Ardelyx stock traded up $0.16 during mid-day trading on Thursday, reaching $4.72. 1,230,396 shares of the stock were exchanged, compared to its average volume of 4,367,811. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -29.47 and a beta of 0.81. The company has a current ratio of 4.58, a quick ratio of 4.31 and a debt-to-equity ratio of 0.87. Ardelyx has a fifty-two week low of $4.02 and a fifty-two week high of $9.33. The firm has a 50-day simple moving average of $5.11 and a 200 day simple moving average of $5.30.

Ardelyx (NASDAQ:ARDX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, meeting analysts' consensus estimates of $0.02. The company had revenue of $116.13 million for the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in Ardelyx by 1.6% during the third quarter. JPMorgan Chase & Co. now owns 387,144 shares of the biopharmaceutical company's stock valued at $2,667,000 after purchasing an additional 6,093 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Ardelyx by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company's stock worth $72,819,000 after acquiring an additional 767,111 shares during the last quarter. Barclays PLC grew its holdings in shares of Ardelyx by 24.9% during the 3rd quarter. Barclays PLC now owns 547,325 shares of the biopharmaceutical company's stock valued at $3,770,000 after purchasing an additional 109,285 shares during the last quarter. Geode Capital Management LLC increased its position in Ardelyx by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 5,487,742 shares of the biopharmaceutical company's stock worth $37,818,000 after purchasing an additional 17,296 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Ardelyx by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,035,135 shares of the biopharmaceutical company's stock valued at $10,318,000 after buying an additional 96,357 shares in the last quarter. 58.92% of the stock is owned by institutional investors.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, CEO Michael Raab sold 41,666 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.36, for a total transaction of $223,329.76. Following the completion of the sale, the chief executive officer now directly owns 1,108,719 shares in the company, valued at $5,942,733.84. This trade represents a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David M. Mott purchased 77,729 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were purchased at an average cost of $5.00 per share, with a total value of $388,645.00. Following the completion of the acquisition, the director now owns 2,015,494 shares in the company, valued at $10,077,470. The trade was a 4.01 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 158,076 shares of company stock worth $823,804. Insiders own 5.90% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.